ArticleCardiology research and practice2011
Mesenchymal stem cells and inflammatory cardiomyopathy: cardiac homing and beyond.
Article in Cardiology research and practice, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- A randomized, open-label, multicenter trial for the safety and efficacy of adult mesenchymal stem cells after acute myocardial infarction.Journal of Korean medical science · 2014Trial
- Senescence of bone marrow mesenchymal stromal cells: a narrative review of mechanisms, functional consequences, and rejuvenation strategies for age-related disorders.Stem cell research & therapy · 2025Review
- Mesenchymal Stem Cell Secretome for Cardiac Regeneration: Opportunity for Cell-Free Therapy.International journal of molecular sciences · 2025Review
- Cell-Based and Selected Cell-Free Therapies for Myocardial Infarction: How Do They Compare to the Current Treatment Options?International journal of molecular sciences · 2022Review
- Surfing the clinical trials of mesenchymal stem cell therapy in ischemic cardiomyopathy.Stem cell research & therapy · 2021Review
- The Potential Properties of Natural Compounds in Cardiac Stem Cell Activation: Their Role in Myocardial Regeneration.Nutrients · 2021Review
- Modulation of the acute defence reaction by eplerenone prevents cardiac disease progression in viral myocarditis.ESC heart failure · 2020Article
- Pulsed electromagnetic fields potentiate the paracrine function of mesenchymal stem cells for cartilage regeneration.Stem cell research & therapy · 2020Article
- Comparative Study of the Therapeutic Potential of Mesenchymal Stem Cells Derived from Adipose Tissue and Bone Marrow on Acute Myocardial Infarction Model.Oman medical journal · 2019Article
- Extracellular vesicles from regenerative human cardiac cells act as potent immune modulators by priming monocytes.Journal of nanobiotechnology · 2019Article
- Interleukin-1Stem cells international · 2019Article
- Mesenchymal stem cells in cardiac regeneration: a detailed progress report of the last 6 years (2010-2015).Stem cell research & therapy · 2016Review
- Mesenchymal Stromal Cell Therapy in Ischemia/Reperfusion Injury.Journal of immunology research · 2015Review
- MCP/CCR2 signaling is essential for recruitment of mesenchymal progenitor cells during the early phase of fracture healing.PloS one · 2014Article
- Mesenchymal stem cells and their chondrogenic differentiated and dedifferentiated progeny express chemokine receptor CCR9 and chemotactically migrate toward CCL25 or serum.Stem cell research & therapy · 2013Article
- Mesenchymal stromal cells but not cardiac fibroblasts exert beneficial systemic immunomodulatory effects in experimental myocarditis.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Under conventional heart failure therapy, inflammatory cardiomyopathy usually has a progressive course, merging for alternative interventional strategies. There is accumulating support for the application of cellular transplantation as a strategy to improve myocardial function. Mesenchymal stem cells (MSCs) have the advantage over other stem cells that they possess immunomodulatory features, making them attractive candidates for the treatment of inflammatory cardiomyopathy. Studies in experimental models of inflammatory cardiomyopathy have consistently demonstrated the potential of MSCs to reduce cardiac injury and to improve cardiac function. This paper gives an overview about how inflammation triggers the functionality of MSCs and how it induces cardiac homing. Finally, the potential of intravenous application of MSCs by inflammatory cardiomyopathy is discussed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.